Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT01408160 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Adult B Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions

DRUG: Cytarabine
BIOLOGICAL: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

Albert Einstein College of Medicine

Collaborators

[object Object]